Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming patent loss and an up-and-coming Rx-to-OTC switch. Crestor, AstraZeneca’s top cholesterol drug with market exclusivity until 2016, slides up one notch to number four, and GSK’s Advair Diskus returns to round out the top five. Tecfidera, predicted to be a blockbuster in Biogen Idec’s multiple sclerosis portfolio, continues to gain strength with a 20 percent climb in sales.

View the full data here…